2017 Annual Meeting
(592d) Engineering Nanoparticle Artificial Antigen Presenting Cells Based on T Cell Biology Improves T Cell Enrichment and Activation for Cancer Immunotherapy
Our design of the aAPCs is centered on a reductionist approach to biomimicry. Originally, our aAPCs were micron-sized to mimic the size of cells; however, this poses a problem for in vivo therapeutics as there is a possibility for embolization. Therefore, our studies herein focus on quantifying the effect of aAPC size and designing an effective nano-sized aAPC based on our understanding of T cells. As a part of our design criteria, we aimed to engineer these aAPCs from iron oxide nanoparticles so that we could magnetically enrich antigen-specific T cells because of their very low frequencyâ1 in 105-106 T cells.
We found consistent with T cell biology that, particles larger than T cell receptor (TCR) clusters of around 300 nm in diameter were more effective at activating CD8+ T cells. These nano-aAPCs also had increased binding through multivalent interactions, which led to an increase in ability to magnetically enrich antigen-specific T cells. Enrichment was also enhanced by tuning particle concentration and only adding antigen-specific signaling molecules to the particles. Synthesizing our findings, we report much higher numbers of antigen-specific T cell generated for cancer therapy with our 300 nm aAPCs. Beyond immunotherapeutic applications, our quantitative and biologically inspired particles provide a case study to guide the design of other cell-modulating technologies.